Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 3
1(20.0%)
Phase 4
1(20.0%)
N/A
1(20.0%)
5Total
Phase 2(2)
Phase 3(1)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06363812Completed

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Role: collaborator

NCT03976518Phase 2Completed

Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)

Role: collaborator

NCT03542461Phase 3Unknown

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

Role: collaborator

NCT03183700Not ApplicableUnknown

Self Collected Sampling in Non-attendees Cervical Cancer Screening: DNA Test and Molecular Triage for HPV Positive Women

Role: collaborator

NCT03219762Phase 2Unknown

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

Role: collaborator

NCT02296255Phase 4Completed

Effect of HPV Vaccination on Women Aged 25 Years

Role: collaborator

All 6 trials loaded